An antiepileptic drug approved decades ago in Estados Unidos shows the potential to stop the progression of Alzheimer disease even before symptoms appear. Pesquisadores identified that levetiracetam prevents the production of the most toxic form of the beta-amyloid protein (Aβ42), responsible for damage to brain cells and the development of senile plaques characteristic of the disease.
The study, carried out by scientists at Universidade Northwestern, used genetically modified animal models, cultures of human neurons and brain tissue from patients with Down syndrome. Essa approach allowed us to map the exact location where Aβ42 accumulates in the synaptic vesicles of neurons. The results indicate that the drug works by modulating a specific protein in synaptic vesicles, altering the processing of the amyloid precursor protein and preventing its transformation into harmful forms.
Patients with Down syndrome are at high risk of developing early-onset Alzheimer due to gene duplication that increases amyloid production. Mais 95% of them manifest the disease by the age of 40. Levetiracetam was effective in reducing the production of this toxic protein in these models, opening perspectives for preventive interventions in high-risk populations.
Mechanism of action of the drug
Levetiracetam binds to the SV2A protein on synaptic vesicles. Essa binding slows down the vesicle recycling process during neuronal signaling. Como result, the amyloid precursor protein remains longer on the cell surface and avoids the internal pathway that leads to the production of Aβ42.
This modulation completely prevents the formation of the harmful protein in experiments with human neurons and animal models. Diferentemente of approved treatments such as lecanemab and donanemab, which remove plaques that have already formed, levetiracetam acts at the source of the problem, preventing initial accumulation.
Importance of early use
Intervention needs to occur long before any detectable signs of the disease appear. Cérebros of people between 30 and 50 years old generally direct proteins to safe pathways. With aging, these defenses weaken, allowing deviations that generate Aβ42, tau tangles, cell death and inflammation.
For patients with already established Alzheimer, the medicine does not reverse irreversible damage. Análises of clinical data show that levetiracetam users experience a delay in the time between cognitive decline and death, but only when started early.
Application in high-risk groups
Individuals with hereditary Alzheimer or Down syndrome represent priority candidates for future testing. The drug could be administered at young ages to block the pathological process before any measurable changes occur through tests.
Researchers develop improved versions of levetiracetam, as the current form is metabolized quickly. Essa improvement aims at greater duration and effectiveness in prevention.
Limitations and next steps
The medicine is not perfect due to its pharmacokinetics. Additional Estudos seek to confirm benefits in high-risk humans with prolonged administration.
The discovery identifies new therapeutic targets to stop Aβ42 production. Ela reinforces the need for preventive strategies focused on the early stages of the pathology.
Perspectives for prevention
Levetiracetam offers an affordable and FDA-approved approach. Sua use in prevention would require close monitoring in specific populations to assess long-term safety.
Research continues to integrate this mechanism into preventive protocols. The emphasis is on intervention before irreversible brain damage occurs.
